Tag: HEA MTC BIO PHA

Myosin Therapeutics Receives FDA Clearance to Initiate First-in-Human Trial of MT-125 in Glioblastoma

JUPITER, Fla., June 9, 2025 /PRNewswire/ -- Myosin Therapeutics, Inc., a clinical-stage biotechnology company developing first-in-class therapies targeting molecular motors, today announced that the...

The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC

CHENGDU, China, June 6, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", 6990.HK) today announced that results from its registrational study (OptiTROP-Lung03) evaluating...

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

Company Expands IP Portfolio While Advancing Clinical Innovation in Oncology Supportive Care Case Study and Interim Clinical Trial Results Will Be Discussed NEW YORK, June 5,...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsHEA MTC BIO PHA

KENT WORLDWIDE™ Celebrates the Grand Opening of the World’s Best Cat Litter® Manufacturing Facility with a Ribbon-Cutting Event

Sustainable Pharmaceutical Packaging Market to reach USD 270.4 billion by 2031, Wissen Research

BMI Investors Have Opportunity to Lead Badger Meter, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Tag: HEA MTC BIO PHA

Myosin Therapeutics Receives FDA Clearance to Initiate First-in-Human Trial of MT-125 in Glioblastoma

The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us